AstraZeneca advice unlikely to change despite rate of rare clotting ‘doubling’

New European research suggests the incidence of a rare blood clotting condition in AstraZeneca vaccine recipients is twice as prevalent as previously reported, but also forecasts the vaccine will still prevent many more deaths than it causes.